Filtered By:
Drug: Allopurinol

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour
Conclusions A dose of 500 mg intravenous allopurinol rapidly crosses the placenta and provides target concentrations in 95% of the fetuses at the moment of delivery, which makes it potentially useful as a neuroprotective agent in perinatology with very little side effects. Trial registration The study is registered in the Dutch Trial Register (NTR1383) and the Clinical Trials protocol registration system (NCT00189007).
Source: Archives of Disease in Childhood - Fetal and Neonatal Edition - February 13, 2014 Category: Perinatology & Neonatology Authors: Kaandorp, J. J., van den Broek, M. P. H., Benders, M. J. N. L., Oudijk, M. A., Porath, M. M., Bambang Oetomo, S., Wouters, M. G. A. J., van Elburg, R., Franssen, M. T. M., Bos, A. F., Mol, B. W. J., Visser, G. H. A., van Bel, F., Rademaker, C. M. A., Derk Tags: Stroke, Medicines regulation Original articles Source Type: research

Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities.
Abstract Stroke is the second leading cause of death, after ischemic heart disease, and accounts for 9% of deaths worldwide. According to the World Health Organization [WHO], 15 million people suffer stroke worldwide each year. Of these, more than 6 million die and another 5 million are permanently disabled. Reactive oxygen species [ROS] have been implicated in brain injury after ischemic stroke. There is evidence that a rapid increase in the production of ROS immediately after acute ischemic stroke rapidly overwhelm antioxidant defences, causing further tissue damage. These ROS can damage cellular macromolecules ...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2013 Category: Drugs & Pharmacology Authors: Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W Tags: CNS Neurol Disord Drug Targets Source Type: research